Literature DB >> 16985721

Biomarkers for early detection and optimized treatment for transitional cell carcinoma.

S J Freedland, M H Bui, D Chao, A J Pantuck, A Zisman, A S Belldegrun.   

Abstract

Entities:  

Year:  2001        PMID： 16985721      PMCID： PMC1476060     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  7 in total

1.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.

Authors:  C N Sternberg; P H de Mulder; J H Schornagel; C Théodore; S D Fossa; A T van Oosterom; F Witjes; M Spina; C J van Groeningen; C de Balincourt; L Collette
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.

Authors:  J L Au; R A Badalament; M G Wientjes; D C Young; J A Warner; P L Venema; D L Pollifrone; J D Harbrecht; J L Chin; S P Lerner; B J Miles
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

3.  Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine.

Authors:  G P Hemstreet; S Yin; Z Ma; R B Bonner; W Bi; J Y Rao; M Zang; Q Zheng; B Bane; N Asal; G Li; P Feng; R E Hurst; W Wang
Journal:  J Natl Cancer Inst       Date:  2001-03-21       Impact factor: 13.506

4.  Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Authors:  D L Lamm; B A Blumenstein; E David Crawford; J D Crissman; B A Lowe; J A Smith; M F Sarosdy; P F Schellhammer; A I Sagalowsky; E M Messing; P Loehrer; H Barton Grossman
Journal:  Urol Oncol       Date:  1995 May-Jun       Impact factor: 3.498

5.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

6.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

7.  Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.

Authors:  H Huland; U Otto; M Droese; G Klöppel
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.